




**ILCA**  
conference

# PROVISIONAL PROGRAMME



**18<sup>th</sup>**  
ANNUAL  
CONFERENCE

UNIFYING MINDS  
**TRANSFORMING CARE**

17-19 October 2024 |  
Toronto, Canada

ILCA  
2024

## REGISTRATION

Registration must be completed online at [Registration – ILCALive](#)

ILCA members benefit from special registration fees. If you'd like to become a member, simply sign up today and benefit from the many advantages and join the ILCA community

Attendee Category	Super Early Bird (until 7 <sup>th</sup> of March)	Early Bird (until 31 <sup>st</sup> of May)	Regular Fee (until 16 <sup>th</sup> of October)	On-Site Fee (17 <sup>th</sup> to 19 <sup>th</sup> October)
ILCA Member	320	420	535	595
Non-Member	520	690	745	800
Student ILCA Member	165	180	215	240
Student Non-Member	206	227	265	290
Nurse / Pharmacist member	165	180	215	240
Nurse / Pharmacist non -member	206	227	265	290
Virtual only fee	258	280	370	370

**ILCA conference** INTERNATIONAL LIVER CANCER ANNUAL CONFERENCE 2024  
TORONTO • CANADA

**18<sup>th</sup> ANNUAL CONFERENCE ILCA 2024**  
UNIFYING MINDS  
TRANSFORMING CARE  
**17 – 19 October 2024**

For More Information – [ilcalive.org](http://ilcalive.org)

CO-LOCATED WITH:  
**CASL STC 2024**  
2024 CASL SINGLE TOPIC CONFERENCE  
ON HEPATOCELLULAR CARCINOMA  
19 – 20 October 2024

We believe that by working together, we can extend the impact of our work worldwide and drive positive change in our field. That is why we offer special rates to encourage you to extend your stay in Toronto, attend both events and expand your knowledge even more!

Registration Type	Regular Registration Rate (ends October 4, 2024)	On-site Registration Rate (from October 5, 2024)
CASL & ILCA Member*	\$ 850.00	\$ 1,000.00
CASL Member - ILCA Non-Member*	\$ 1,100.00	\$ 1,250.00
Trainee	\$ 300.00	\$ 375.00
Nurse/Allied Healthcare Professional	\$ 380.00	\$ 450.00

\*Please contact [casl@hepatology.ca](mailto:casl@hepatology.ca) to obtain your member code

## REGISTRATION

### VIRTUAL REGISTRATION: UNABLE TO JOIN US IN TORONTO?

Participate virtually in **ILCA24** and access sessions from the comfort of your own space.

Please note that the sessions are not live streamed, but with the Virtual Pass you will have access to the recordings which will be available 48 hours after the end of the Conference.



## VENUE & ACCOMMODATION

The venue for the ILCA 2024 Annual Conference is the **Hilton Hotel in Toronto.**

Please visit <https://ilcalive.org> for future information and for hotel reservations.

Through this website you can reserve, modify or cancel your reservations at any time and receive updated information about the event.

**We look forward to seeing you!**



[Get in touch!](#)



[Book your stay](#)



## SCIENTIFIC PROGRAMME

### DAY 1

THURSDAY 17<sup>TH</sup> OF OCTOBER 2024

11:00 – 11:05	<b>ILCA AC2024 Opening Ceremony</b> Tim Meyer, ILCA President, MD, PhD, (UK)
11:15 – 13:15	<b>Bench To Bedside: Emerging Therapeutic Targets</b> <b>Introduction from session chairs</b> Valerie Chew, MD, PhD (Singapore) Tim Greten, MD (USA) <b>11.15 - 11.30</b> <b>Metformin for the treatment of NASH - HCC</b> Tim Greten, MD (USA) <b>11.30 - 11.45</b> <b>Anti - TIGIT for HCC</b> Carmen Wong, MD (Hong Kong) <b>11.45 - 12.00</b> <b>Tumor associated macrophages via PI3K - gamma inhibition to enhance immunotherapy for HCC</b> Su Jong Yu, MD (Korea) <b>12.00 - 12.15</b> <b>Metabolic reprogramming of CCA and therapeutic implications</b> Chiara Braconi, MD, PhD (UK) <b>12.15 - 12.30</b> <b>Future of immunotherapy for liver cancer</b> Tak W. Mak, MD (Canada) <b>12.30 - 12.45</b> <b>Cancer vaccines in hepatocellular carcinoma - is there a role among the immune oncology landscape?</b> Toh Han Chong, MD (Singapore) <b>12.45 - 13.00</b> <b>Anti - GPC CAR - T cells in HCC</b> Mitchell Ho, PhD (USA) <b>13.00 - 13.15</b> <b>Panel Discussion</b>
13:15 – 14:00	<b>Poster Tour &amp; Lunch Break</b>
14:00 – 14:30	<b>Clinical State of the Art</b> <b>Goals and endpoints in liver cancer clinical trials</b> Bruno Sangro, MD, PhD (Spain)
14:30 – 16:00	<b>General Session 1 – Molecular Pathogenesis, Cell Biology and Translational Research</b> <b>4 oral presentations</b> from ILCA AC2024 accepted abstracts. <b>8 Poster blast.</b> 8 selected poster presenters will introduce their poster in «3 minutes pitch».
16:00 - 16:30	<b>Coffee Break &amp; Networking</b>

## SCIENTIFIC PROGRAMME

DAY 1 - THURSDAY 17<sup>TH</sup> OF OCTOBER 2024

16:30 – 17:30	<p><b>Management of Unresectable Liver Localized</b></p> <p><b>16:30 - 16:32</b> <b>Introduction from session chairs</b> Bruno Sangro, MD, PhD (Spain) Joycelyn Lee, PhD (Singapore)</p> <p><b>16.32 - 16.44</b> <b>The story of SIRT – Should recent efficacy data erase our memory of prior failed trials?</b> Riad Salem, MD (USA)</p> <p><b>16.44 - 16.56</b> <b>Immune modulation for BCLC B: combining ICI and transarterial treatments</b> Stephen Chan, MD, PhD, FAHA (Hong Kong)</p> <p><b>16.56 - 17.08</b> <b>Patient selection for LRT: How do you define TACE/TARE unsuitable in 2023?</b> Edward Kim, MD (USA)</p> <p><b>17.08 - 17.20</b> <b>What is the role for locoregional therapies in patients iCCA?</b> Marina Baretta, MD (USA)</p> <p><b>17.20 - 17.30</b> <b>Panel Discussion</b></p>
17:30 – 18:30	<p><b>Bayer Industry Symposium</b></p>
18:30 – 19:30	<p><b>Y-ILCA Career Development Roundtables &amp; Welcome Reception</b> Session organised by the Y-ILCA Committee with the aim of helping young investigators improve their academic and research skills and broaden their academic network.</p> <p>2 roundtables with different topics, each with 2 senior experts from different geographical backgrounds that will interact with young investigators in small groups to explore the topic for an hour.</p> <p><b>RoundTable 1: Basic Science &amp; Translational Research</b> Valerie Chew, MD, PhD (Singapore) Chiara Braconi, MD, PhD (UK)</p> <ul style="list-style-type: none"><li>• How to get started with an academic career in basic science: choosing the right research niche.</li><li>• Strategies on study design &amp; finding a good mentor</li><li>• Tips on grant applications</li><li>• Translating your research to an early phase clinical trial</li><li>• Presenting basic science well</li><li>• Publishing in a high impact journal</li><li>• Leadership skills &amp; how to set up your own research group</li><li>• How to manage work/life balance and clinical work/research</li></ul> <p><b>RoundTable 2: Clinical</b> Grainne O’Kane, MD (Canada) Marina Baretta, MD (USA)</p> <ul style="list-style-type: none"><li>• How to get started with a clinical academic career in liver cancer</li><li>• Choosing the right research area &amp; finding a good mentor</li><li>• How to get involved in clinical trials</li><li>• How to build international research networks</li><li>• Tips on grant applications &amp; publishing in a high impact journal</li><li>• How to manage clinical work and research</li><li>• Leadership skills &amp; how to set up your own research group</li><li>• Settlement of a multidisciplinary tumour board in your centre</li></ul> <p><b>19.00 - 19.30</b> <b>ILCA AG2024 WELCOME RECEPTION</b></p>

## SCIENTIFIC PROGRAMME

### DAY 2

FRIDAY 18<sup>TH</sup> OF OCTOBER 2024

08.30 – 09.30	<b>EISAI Breakfast Industry Symposium (breakfast available from 08:00)</b>
09.30 – 10.30	<b>Translational Spotlight on CCA</b> <b>09.30 - 09.32</b> <b>Introduction from session chairs</b> Chiara Braconi, MD, PhD (UK) Arndt Vogel, MD (Germany) <b>09.32 - 09.44</b> <b>Overcoming Primary and Secondary Resistance to FGFR2 fusions</b> Anna Saborowski, MD (Germany) <b>09.44 - 09.56</b> <b>Preclinical models of cholangiocarcinoma – what have we learned</b> Luke Boulter, Dr (UK) <b>09.56 - 10.08</b> <b>Molecular and Genomic Features of CCA: Implications for treatment</b> Chiara Braconi, MD, PhD (UK) <b>10.08 - 10.20</b> <b>Liquid Biopsy epigenetic profiling for cancer subtyping</b> Jacob Berchuck, MD (USA) <b>10.20 - 10.30</b> <b>Questions &amp; answers</b>
10.30 – 11.00	<b>Coffee Break &amp; Networking</b>
11.00 – 11.30	<b>ILCA Advocacy</b> Chair: Bruno Sangro, MD, PhD (Spain) <b>11.00 - 11.10</b> <b>The intricated pathways to access drug therapies in HCC</b> Manon Allaire, Dr (France) <b>11.10 - 11.20</b> <b>Needs from Patients in Central, Southern and West Africa</b> Adwoa Adjei - Nkansah, Dr (Africa) <b>11.20 - 11.30</b> Melinda Bachini, Patient Advocate (USA)
11.30 – 12.00	<b>Presidential Address and Awards Ceremony</b> <ul style="list-style-type: none"><li>· <b>Nelson Fausto Award Announcement</b></li><li>· <b>Junior investigator Awards:</b><ul style="list-style-type: none"><li>· Best oral presentation (clinical)</li><li>· Best oral presentation (basic/translational)</li><li>· Best poster (clinical)</li><li>· Best poster (basic/translational)</li></ul></li></ul>

## SCIENTIFIC PROGRAMME

DAY 2 - FRIDAY 18<sup>TH</sup> OF OCTOBER 2024

12.00 – 13.00	<b>General Session 2: Epidemiology, Staging and Prognosis</b> 4 oral presentations from ILCA AC24 accepted abstracts.
13.00 – 14.00	<b>Roche Industry Symposium and Lunch Break</b>
14.00 – 15.00	<b>ILCA Debates</b> <b>Introduction from session chairs</b> Amit Singal, MD (USA) David Pinato, MD, PhD (UK) <b>Debate 1: Combination Therapy vs Sequential Therapy in intermediate stage-HCC</b> Jordi Bruix, MD (Spain) and Katie Kelley, MD (USA) <b>Debate 2: An RCT for HCC surveillance is necessary and feasible</b> Maria Reig, MD, PhD (Spain) and Nicole Rich, MD (USA)
15.00 – 16.00	<b>General Session 3: Surveillance and Diagnosis</b> 4 oral presentations from ILCA AC2024 accepted abstracts.
16.00 – 16.15	Coffee Break & Networking
16.15 – 17.15	<b>Tumor Board</b> <b>Introduction from session chairs</b> Anjana Pillai, MD (USA) Neehar Parikh, MD, MS (USA) <b>Tumor board case 1: Peds tumor case</b> Experts: Peng Wu, MD (USA) and Blayne Sayed, MD, PhD (Canada) <b>Tumor board case 2: Mixed HCC-CCA</b> Experts: Adam Yopp, MD (USA), David Pinato, MD, PhD (UK), Parissa Tabrizian, MD (USA) and Laura Kulik, MD (USA) <b>Tumor board case 3: Borderline resectable HCC</b> Experts: Adam Yopp, MD (USA), David Pinato, MD, PhD (UK), Parissa Tabrizian, MD (USA) and Laura Kulik, MD (USA)
17.15 – 18.15	<b>AstraZeneca Industry Symposium</b>
18.15 – 18.45	<b>Y-ILCA Masterclass – It's not all about writing: how to communicate science effectively</b> <b>Session organised by the Y-ILCA Committee with the aim of helping young investigators improve their academic and research skills and broaden their academic network.</b> Arndt Vogel, MD (Germany)
18:45 – 19.30	General Assembly (ILCA members only)

## SCIENTIFIC PROGRAMME

### DAY 3

SATURDAY 19<sup>TH</sup> OF OCTOBER 2024

09.30 – 10.30	<p><b>Clinical Symposium – Comprehensive management of the patient: Beyond HCC-directed therapy</b> <b>Introduction from session chairs</b> Stephen Chan, MD, PhD, FAHA (Hong Kong) Anand Kulkarni, MD, FACC (India)</p> <p>09.30 - 09.42 <b>Case presentation: Early stage/BCLC stage A HCC in an elderly with multiple comorbidities and weight loss + decision on ablation</b> Adwoa Adjei-Nkansah, Dr (Africa)</p> <p>09.42 - 09.54 <b>Evaluation of Frailty and Impact of Frailty on Treatment Outcome</b> Puneeta Tandon, MD (Canada)</p> <p>09.54 - 10.06 <b>Role of nurse in patient's journey</b> Neus Llarch (Spain)</p> <p>10.06 - 10.18 <b>Case Presentation: Worsening Condition</b> Adwoa Adjei-Nkansah, Dr (Africa)</p> <p>10.18 - 10.30 <b>Evidence-based Palliative care for HCC</b> Hong Jae Chon, MD, PhD (Korea)</p>
10.30 – 11.00	Coffee Break & Networking
11.00 – 11.30	<p><b>Basic State of the Art</b> <b>AI in Medicine</b> Mamatha Bhat MD, MSc, PhD, FRCPC (Canada)</p>
11.30 – 12.30	<p><b>General Session 4: Therapy &amp; Miscellaneous</b> <b>4 oral presentations</b> from ILCA AC2024 accepted abstracts.</p>
12.30 – 13.15	<p><b>Surgical resection: East meets West</b> <b>Introduction from session chairs</b> Gonzalo Sapisochin, MD, PhD, MSc (Canada) Albert Chan, MD (Hong Kong)</p> <p>12:30 -12:40 <b>Advances in resection for liver cancer (HCC and CCA) and future of resectability in era of (neo)adjuvant therapies</b> Osamu Itano, MD, PhD (Japan)</p>



## SCIENTIFIC PROGRAMME

DAY 3 - SATURDAY 19<sup>TH</sup> OF OCTOBER 2024

12.30 – 13.15	<p>12:40 - 12:50 <b>Role of (neo)adjuvant therapy for HCC (including TACE/TARE)</b> Grainne O’Kane, MD (Canada)</p> <p>12:50-13:00 <b>Future of Resectability for HCC using (neo)adjuvant therapies</b> Albert Chan, MD (Hong Kong)</p> <p>13:00 - 13:10 <b>Transplant for HCC and CCA, including IO prior to transplant</b> Anjana Pillai, MD (USA)</p> <p>13:10-13:15 <b>Panel discussion</b></p>
13.15 – 14.15	<p><b>Merck Industry Symposium and Lunch break</b></p>
14.15 – 15.30	<p><b>ILCA, AASLD and CASL joint symposium: Prevention and Surveillance</b></p> <p>14.15 -14.17 <b>Introduction from session chairs</b> Anjana Pillai, MD (USA) Nicole Rich, MD (USA)</p> <p>14.17 - 14.29 <b>Strategies for HCC prevention, including in non-viral liver disease</b> George Ioannou, MD (USA)</p> <p>14.29 - 14.41 <b>Emerging approaches to HCC surveillance</b> Amit Singal, MD (USA)</p> <p>14.41 - 14.53 <b>Precision Surveillance: close to reality?</b> Neehar Parikh, MD, MS (USA)</p> <p>14.53 - 15.05 <b>Recall systems and linkage to care: Important steps after surveillance</b> Maria Reig, MD, PhD (Spain)</p> <p>15.05 - 15.17 <b>System and population-level approaches to prevention and surveillance</b> Jordan Feld, MD, MPH (Canada)</p> <p>15.17 - 15.30 <b>Questions &amp; Answers</b></p>

## SCIENTIFIC PROGRAMME

DAY 3 - SATURDAY 19<sup>TH</sup> OF OCTOBER 2024

15.30 – 16.30	<p><b>Treatment Response Biomarkers</b></p> <p>15.30 - 13.32 <b>Introduction from session chairs</b> Maria Reig, MD, PhD (Spain) Ju Dong Yang, MD (USA)</p> <p>15.32 - 15.44 <b>Role of imaging for assessing treatment response?</b> Mishal Mendiratta-Lala, MD (USA)</p> <p>15.44 - 15.56 <b>Application of AI in pathology for treatment response prediction</b> Julien Calderaro, MD (France)</p> <p>15.56 - 16-08 <b>Molecular-based prediction biomarkers in HCC: current status</b> Josep Maria Llovet, MD, PhD (Spain)</p> <p>16.08 - 16.20 <b>Liquid biopsy for minimal residual disease in HCC</b> Augusto Villanueva, MD, PhD (USA)</p> <p>16.20 - 16.30 <b>Questions &amp; answers</b></p>
16.30 – 16.40	<p><b>Closing Address</b> Tim Meyer, ILCA President, MD (UK)</p>

## THANK YOU TO OUR SPONSORS AND SUPPORTERS FOR THEIR SUPPORT

### ILCA 2024 PRINCIPAL SPONSOR



### ILCA 2024 CONFERENCE SPONSOR



### ILCA 2024 CONFERENCE SUPPORTERS



### ILCA 2024 INDUSTRY PARTNERS

Liver cancer incidence rates are rapidly increasing across the world. And, because it is rarely detectable early, when it is most treatable, any liver cancer is difficult to cure. Our industry partnership programme for 2024 offers healthcare companies the platform from which to support ILCA's mission and values through educational, scientific activities and events. We offer a strategic forum for high-level dialogue between ILCA leadership and industry partners to discuss the key issues for the future of liver cancer treatment, as well as recognition of your year-round partnership support.





JOIN THE **ILCA COMMUNITY** AND  
REGISTER FOR THE CONFERENCE.

**WE CAN'T WAIT TO SEE YOU IN TORONTO!**

## Contact Us

International Liver Cancer Association (ILCA)  
Avenue des arts, 47  
B-1000 Brussels – Belgium

Tel: +32 (0)2 320 2531

Email: [info@ilca-online.org](mailto:info@ilca-online.org)

Website: [www.ilca-online.org](http://www.ilca-online.org)